GLP1 et Goût

TerminatedPhase 4

Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes

Comparative Study of Gustatory Performance, Sensory Specific Satiation, Liking and Wanting in Patients With Type 2 Diabetes

Lead sponsor

Centre Hospitalier Universitaire Dijon

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers, Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≥27•HbA1c ≥7%•Healthy volunteers

Primary endpoint

•Modifications in wanting

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02674893

Org study IDBRINDISI 2013

Timeline

Milestones

Study start2014-02-04actual

Study first posted2016-02-05estimated

Primary completion2016-08-31actual

Study completion2016-08-31actual

Last update posted2026-02-09actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Healthy volunteersObesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

DIABETIC PATIENTS TREATED WITH LIRAGLUTIDE

•persons who have provided written informed consent

•aged > 18 years

•type 2 diabetes with HbA1C > 7%

•overweight (BMI > 27)

•normal renal function (creatinine clearance > 50ml/min)

•patients to be treated with Liraglutide (patients with type 2 diabetes with HbA1C > 7.5% and overweight or obesity, whose current treatment is insufficient to control the diabetes).

CONTROL DIABETIC PATIENTS

•persons who have provided written informed consent

•aged > 18 years

•type 2 diabetes with HbA1C > 7%

•overweight (BMI > 27)

•patients for whom treatment with Liraglutide is not indicated

•normal renal function (creatinine clearance > 50ml/min)

HEALTHY SUBJECTS

•persons who have provided written informed consent

•aged > 18 years

Exclusion criteria

DIABETIC PATIENTS TREATED WITH LIRAGLUTIDE

•type 1 diabetes

•decompensated congestive heart failure

•acute or chronic infection, progressive cancer, liver cirrhosis

•ongoing treatment with antibiotics

•smoking

•chronic alcohol abuse (>4 glasses a day)

•aversion to the products to be eaten or smelled

•poor understanding of the cognitive tasks requested

•treatment interfering with olfactogustatory performance, such as psychotropic, anti-emetic and anti-ulcer drugs

•persons without national health insurance cover

•persons under guardianship

•hypersensitivity to Liraglutide

•pregnancy, breastfeeding

•history of acute or chronic pancreatitis

•calcitonin level at selection ≥ 50 ng/L

•liver disease, defined by a level of alanine aminotransferase (ALAT) ≥ 2.5 times the upper limit of normal (ULN) for reference values

CONTROL DIABETIC PATIENTS

•type 1 diabetes,

•decompensated congestive heart failure,

•acute or chronic infection, progressive cancer, liver cirrhosis,

•ongoing treatment with antibiotics,

•smoking

•chronic alcohol abuse (> 4 glasses a day),

•aversion to the products to be eaten or smelled,

•poor understanding of the cognitive tasks requested,

•treatment interfering with olfactogustatory performance, such as psychotropic, anti-emetic and anti-ulcer drugs.

•persons without national health insurance cover

•persons under guardianship

HEALTHY SUBJECTS

•diabetes (type I and II)

•sensory disorders

•decompensated congestive heart failure,

•acute or chronic infection, progressive cancer, liver cirrhosis,

•ongoing treatment with antibiotics,

•smoking

•chronic alcohol abuse (> 4 glasses a day),

•aversion to the products to be eaten or smelled,

•poor understanding of the cognitive tasks requested,

•treatment interfering with olfactogustatory performance (psychotropic, anti-emetic, anti-ulcer drugs)

•persons without national health insurance cover

•persons under guardianship

•contra-indications to MRI, notably, but not limited to: pace maker, implantable cardiac defibrillators, neurostimulators, cochlear implants, certain implanted automated injection systems (insulin pumps), vascular intracerebral ferromagnetic clips, certain systems to regulate intravascular temperature, myopia requiring the patients to wear spectacle, history of stroke or transient ischemic attack (TIA), metallic foreign body, in particular intraocular or situated near high-risk zones (nervous system, vascular system), claustrophobia….

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Weight & body composition

Patient-reported / QoL

Weight & body composition

1 endpoint

Secondary/protocol endpoint/low confidence

Anthropometric modifications

Time frame:Until 3 months

change from baseline, improvement

Patient-reported / QoL

1 endpoint

Primary/protocol endpoint/low confidence

Modifications in wanting

Time frame:Up to 3 months

change from baseline, improvement

Other clinical outcomes

4 endpoints

Secondary/protocol endpoint/low confidence

Modifications in gustatory performance

Time frame:Until 3 months

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Modifications in liking

Time frame:Until 3 months

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Modifications in salivation following the presentation of foods

Time frame:Until 3 months

change from baseline, descriptive

Secondary/protocol endpoint

Modifications in optimal preferences for sweet and fatty tastes

Time frame:Until 3 months

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Proof of concept: Effect of GLP-1 agonist on food hedonic responses and taste sensitivity in poor controlled type 2 diabetic patients.
Diabetes & metabolic syndrome2019 Jul-Aug (year)PMID31405666doi:10.1016/j.dsx.2019.06.021via CT.gov reference + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.